SPTLC1 and macular telangiectasia type 2: As discussed, multiple metabolic genes contribute to the development of MacTel, including PHGDH and SPTLC1 (in serine and sphingolipids metabolism), so it may be of considerable therapeutic value to explore metabolic targets as treatments of this disease based on outcomes discussed above for other retinal diseases.